Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why are These Five Stocks Deep in Green Territory on Thursday?

Page 1 of 2

U.S. stocks are slowly but surely heading lower today, with the market under pressure following a sharp decline in oil prices. There are several companies that defy today’s downtrend and we’ll find out why in this article. Let’s see what prompted investors to push Eyegate Pharmaceuticals Inc (NASDAQ:EYEG), Constellium NV (NYSE:CSTM), Navios Maritime Holdings Inc. (NYSE:NM), Sophiris Bio Inc (NASDAQ:SPHS) and Yelp Inc (NYSE:YELP) higher today.

stocks, analysis, market, numbers, business, ticket, trade, money, price

photofriday/Shutterstock.com

In the eyes of most traders, hedge funds are assumed to be underperforming, old investment tools of the past. While there are more than 8,000 funds in operation at present, Insider Monkey looks at only the aristocrats of this group, around 730 funds. Contrary to popular belief, Insider Monkey’s research revealed that hedge funds underperformed in recent years because of their short positions as well as the huge fees that they charge, not because they are not good at picking stocks on the long side of their portfolios. Hedge funds did in fact manage to outperform the market on the long side of their portfolios. In fact, the 15 most popular small-cap stocks among hedge funds has returned 102% since the end of August 2012, beat the S&P 500 Index by 53 percentage points (see more details here).

Shares of Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) opened higher today and have surged by as much as 39%, following the release of the company’s 2015 third quarter financial report. Eyegate posted a net loss of $1.4 million, compared to a profit of $0.3 million for the same period last year. The company also announced a licensing agreement with a subsidiary of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for EGP-437, the company’s first and only product so far. Eyegate has also said that proceed of $8.8 million from a public offering completed in August will be used for expenses related to further testing of the product.

Follow Eyegate Pharmaceuticals Inc (NASDAQ:EYEG)
Trade (NASDAQ:EYEG) Now!

Constellium NV (NYSE:CSTM) shareholders are all smiles today, as the stock has surged by as much as 20% during the first hours of trading. This comes as a surprise, as the company’s third quarter results released yesterday after market close missed Wall Street expectations. Revenues came in at $1.41 billion, below estimates of $1.46 billion, while profits turned negative as the company registered a loss of $0.48 per share, versus expectations of a $0.06 per share profit. So far this year, shares have shed 48% of value and are currently trading at $8.60 per share.

Follow Constellium N.v.
Trade (:) Now!

According to our database, 25 elite funds held Constellium NV (NYSE:CSTM) in their portfolios at the end of June, having snapped up 31.5% of the company’s common stock. Phill Gross and Robert Atchinson, the managers of Adage Capital Management, like this company a lot and have boosted their stake by 49% over the second quarter to amass 8.32 million shares.

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!